NKGen Biotech Reports First Patient Dosing with SNK01 in P-I/IIa Study for Treating Moderate Alzheimer’s Disease
Shots:
- NKGen Biotech dosed first patient with SNK01 in the P-I/IIa study investigating safety, efficacy, MTD and/or RP2D for the treatment of moderate Alzheimer’s disease (AD)
- In P-I dose-escalation safety study, SNK01 exhibited improved neuroinflammation and cognitive function in Alzheimer's Disease patients
- SNK01 is an innovative, patient specific ex vivo expanded autologous natural killer (NK) cell, immunotherapeutic drug candidate that is also under development for the treatment of wide range of cancers
Ref: NKGen Biotech | Image: NKGen Biotech
Related News:- Merck KGaA Expand its Collaboration with NKMax to Evaluate the Combination of SNK01 + Erbitux (cetuximab) for Metastatic NSCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.
![Life Molecular Imaging’s [18F] PI-2620 Gains the US FDA’s Fast Track Designation for PET Imaging in Various Neurodegenerative Disorders](https://pharmashots.com/public/images/20240829173251_original_43.webp)
